Metformin/Atorvastatin Combination Therapy in Subjects With Type II Diabetes and Dyslipidemia (Phase 3)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 185 participants.

Also called NCT02947620

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 185 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02947620
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02947620. Randomized; double masking; primary purpose treatment. Start 2015-08 (registry gives no type); primary completion 2017-02-27 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Metformin/Atorvastatin Combination Therapy in Subjects With Type II Diabetes and Dyslipidemia (Phase 3)
Condition
Type II Diabetes
Condition
Dyslipidemia
Intervention (Drug)
Metformin/Atorvastatin 1500mg/40mg, QD
Intervention (Drug)
Metformin 1500mg, QD
Intervention (Drug)
Atorvastatin 40mg, QD
Lead sponsor
Daewoong Pharmaceutical Co. LTD. (class: industry)

Record details

Record id
cardio:ct-nct02947620
Content hash
cd2f12c3e315833a04ad3fc783b8a55cbf1804b1b0597dbc27be48771c1acb4d